In the early 1970s, an alteration in reactivity of maternal lymphocytes was detected in mice as early as 4 h after mating (Morton et al., 1974 (Morton et al., , 1976 . This effect was found to be due to a soluble factor(s) in serum which was termed early pregnancy factor (EPF).
At the time, this was quite a revolutionary discovery. Prevailing orthodoxy held that maternal recognition of pregnancy did not occur until implantation; prior to this, the embryo was thought to be merely a silent passenger in the maternal reproductive tract. It is now known that there is extensive cross-talk between mother and embryo throughout the preimplantation period. However, EPF is still one of the earliest manifestations of this changed physiological status of the mother, opening a unique diagnostic window on this stage of pregnancy.
The other aspect of the discovery that stimulated considerable scientific interest was the demonstration that EPF targeted cells of the maternal immune system. It may be part of the mechanism (still not fully understood) whereby the antigenically alien fetus escapes detection and subsequent rejection by normal maternal immune surveillance processes. If so, then as a benign, natural immunosuppressant, EPF may have wide potential application, for example in controlling the self-destructive effects of autoimmune disease or promoting acceptance of transplanted organs and tissue. Alternatively, since tumour cells are thought to mimic some of the devices used by embryos to evade normal surveillance mechanisms, EPF may facilitate host acceptance of tumours; in this case, antagonizing its effects could have significant therapeutic consequences.
EPF appeared to be an important molecule with great potential, both basic and applied, and our laboratory set out to purify and characterize it. In this review I document this 20 year quest (undertaken by myself in association with Halle Morton, who made the original discovery of EPF, as well as a number of coresearchers), highlighting the most important milestones and describing recent work. The story is highly reminiscent of the discovery and identification of the new generation of growth factors and cytokines. We found that EPF was an extraordinarily potent molecule(s) present in miniscule amounts in biological source materials. Its behaviour was different from that of classic hormones and it could be detected only by an esoteric, capricious and labour-intensive bioassay. Isolation of such a molecule was a formidable task which ultimately revealed that EPF is very similar to chaperonin 10 (cpn10). In conclusion, the implications of this surprising identification are discussed.
Biological background
The bioassay for EPF, the rosette inhibition test, is based on the demonstration by Bach and Antoine (1968) , that an immunosuppressive antilymphocyte serum (ALS) can inhibit, in vitro, spontaneous rosette formation between lymphocytes and heterologous red blood cells. A modification to detect EPF was introduced after it was shown that lymphocytes, preincubated in EPF, give a significantly higher rosette inhibition titre with an ALS than do lymphocytes from the same donor without EPF pretreatment (Morton et al., 1974 (Morton et al., , 1976 (Morton et al., , 1987 .
With this assay, EPF was detected in serum of all mammals tested, within 24-48 h of fertilization (reviewed in Morton et al., 1987) . EPF was closely associated with embryonic wellbeing, appearing in serum within 12 h of embryo transfer and disappearing within 24-48 h of death or removal of the embryo (Morton et al., 1987 Early pregnancy factor (EPF) is a secreted substance with growth regulatory and immunomodulatory properties. It is required for successful establishment of pregnancy and for proliferation of both normal and neoplastic cells, in vivo and in vitro. The rosette inhibition test was used as a bioassay, and the appearance of EPF in serum in the very early stages of pregnancy (in mice, within 4-6 h of mating) was first described two decades ago. However, because of the difficulty of this bioassay and the paucity of EPF in biological materials, the primary structure of the molecule has been identified only recently. Seventy per cent of the amino acid sequence of EPF derived from human platelets was determined. With the exception of a single residue, this was identical to the sequence of rat mitochondrial chaperonin 10 (cpn10). Cpn10 is a heat shock protein that functions as a molecular chaperone. It binds to and stabilizes cpn60 and, in concert, these molecules mediate protein folding in mitochondria, chloroplasts and bacteria. Characterizing EPF as an extracellular form of cpn10 raises unprecedented questions about the mechanism of action. It may be that, as a molecular chaperone in the extracellular compartment, EPF can functionally modify other proteins, serving as a regulator of regulators.
failure to fertilize and failure to implant, as well as in monitoring 'at risk' pregnancies. It was soon found that production of EPF was not confined to pregnancy (Morton et al., 1987 (Morton et al., , 1992 and references therein). It could be detected in serum of patients and animals bearing a variety of tumours and in medium conditioned by all neoplastic and transformed cell lines tested. Production in vitro was associated with growth; it peaked during the logarithmic phase of cell proliferation and ceased after induction of growth arrest or differentiation. This close correlation with embryonic and tumour cell growth prompted the question, is EPF required in these circumstances or is it simply a by-product of cell division?
To answer this, production of monoclonal antibodies, which could be used as specific neutralizing agents in experiments in vitro and in vivo, was undertaken. Although only partially purified antigen was available (prepared from medium conditioned by the choriocarcinoma cell line BeWo), the monoclonal technique facilitated selection of specific clones producing only antibody with EPF-neutralizing capacity. Our experiences in making these antibodies, as well as subsequent experiments in mice and rats, which examined the consequences of removing EPF from various biological situations (Morton et al., 1987 (Morton et al., , 1992 and references therein), were a major turning point in the research.
These studies revealed that EPF is required at first cleavage of the embryo, where its effects appear to be on a maternal response rather than on the embryo itself. In addition, EPF is needed for successful implantation of the embryo and for establishment and continued growth of transplanted tumour cells. In these instances, EPF exerts a direct effect, since trophoblast outgrowth (Athanasas-Platsis, 1993) and proliferation of tumour cells were significantly inhibited by culture in vitro with anti-EPF antibodies. As well as responding to EPF, these cells also produce it. This is the hallmark of a classic autocrine growth factor and implies that EPF would play a role in normal processes of tissue renewal. This was confirmed using the model of liver regeneration following two-thirds partial hepatectomy in rats (Quinn et al., 1994) . We also investigated (Cavanagh et al., 1991) the source of a potent mix of growth factors used during wound healing, namely platelets (Falanga, 1993) . As with plateletderived growth factor and transforming growth factor β, this provided the breakthrough we had been looking for -a relatively plentiful and rich source material from which to isolate sufficient EPF for primary characterization.
Isolation and characterization of EPF
By the early 1990s, nine attempts (including two from our laboratory) at the isolation of EPF from a variety of source materials had been published (reviewed in Morton et al., 1992) . None provided the primary structure of the biologically active molecule and the activity of most of these preparations reflected the presence of a very minor contaminant. One laboratory concluded that assigning EPF activity to a single serum component was inappropriate and proposed a complex scheme in which activity resulted from the interaction of an existing serum component (thioredoxin) and active leukotrienes induced by embryo-derived platelet activating factor (Clarke et al., 1991 and references therein) . This erroneous conclusion reflects a number of difficulties in interpretation of the EPF bioassay (discussed in Cavanagh et al., 1991; Morton et al., 1992 and references therein) but it contains the interesting observation that thioredoxin, while itself inactive, has an inhibitory effect in the EPF bioassay. This finding suggests that thioredoxin could be a regulator of EPF (although the effect must be indirect, since EPF does not contain any cysteine residues).
All major classes of source material with activity in the EPF bioassay (Fig. 1) , including the archetypal sources, pregnancy serum and urine, were fractionated in parallel to ensure that the active molecule from platelets was truly representative of EPF Quinn et al., 1994) . The identical biochemical and immunological behaviour displayed by all provided the assurance that the bioassay was detecting a single substance, or a closely related family of substances, acting in diverse biological situations. However, the only materials providing sufficient EPF to study at the protein, as opposed to the activity, level were platelets and regenerating liver (Quinn et al., 1994) . From 300 units human platelets (1 unit represents platelets from a single blood donation of approximately 500 ml), 45 µg EPF was isolated with a purification factor greater than 10 4 times. The high degree of homogeneity of the preparation was demonstrated by both SDS-PAGE (Fig. 2a) and mass spectrometry (Fig. 2b) , and the latter also provided a precise determination of molecular mass -10.843 kDa. After proteolytic cleavage, the amino acid sequence of approximately 70% of the molecule was identified (Fig. 2c) . With one exception, this was identical to rat mitochondrial cpn10 (Hartmann et al., 1992) and the determined molecular mass was consistent with this being the only difference. In light of known properties of chaperonins (discussed below), this was a surprising result. Nevertheless, further experiments with Tissues that produce early pregnancy factor (EPF) and stimulants that induce its production. EPF is produced from sources shown on the left of the figure in response to a specific releasing factor. For example, platelet activating factor (PAF) acts on platelets while ovum factor from fertilized eggs, in co-operation with prolactin, acts on the ovary. For sources shown on the right of the figure, cell division appears to be a direct stimulus. purified rat cpn10 and its functional associate cpn60 demonstrated that EPF is a functional, as well as a structural, homologue of cpn10; EPF activity, however, is a property of eukaryote but not prokaryote cpn10 . Very recently, we have cloned a cDNA for EPF from a human melanoma library, confirming the single amino acid difference between human EPF and rat cpn10. Recombinant protein has been prepared in Eschericia coli and studies in vitro and in vivo were performed. These establish that the recombinant molecule displays the dual nature of native EPF, exhibiting properties of both EPF and cpn10 (R. M. Murphy, A. I. Cassady, K. M. Summers, M. J. Somodevilla-Torres, N. C. Hillyard, H. Morton and A. C. Cavanagh, unpublished) . With this abundant source of pure EPF, it is now possible to explore thoroughly the potential promise of EPF and return full circle to elucidate its effects on the immune response.
Chaperonin 10
Cpn10 is a heat shock protein (hsp) (Lindquist and Craig, 1988) which functions as a molecular chaperone (Ellis and van der Vies, 1991) . It acts in concert with cpn60 to mediate protein folding in mitochondria and chloroplasts in an ATP-dependent reaction cycle; the homologous molecules in E. coli are known as groES and groEL, respectively (Zeilstra-Ryalls et al., 1991) . Cpn60 is the primary chaperone of this class, recognizing a variety of substrates (unfolded or partially folded proteins); cpn10 reacts only with cpn60, stabilizing cpn60 function and facilitating release of the folded protein at an appropriate stage. Molecular chaperones are known to be involved in protein folding, targeting and assembly throughout the cell (Ellis and van der Vies, 1991), but there is a growing awareness that, with the capacity to bind to and alter the conformation of other proteins, chaperones may play a key role in many other cellular processes.
Heat shock proteins are highly conserved molecules that play vital roles in all cells (Lindquist and Craig, 1988) . Concentrations of hsps are rapidly induced or increased in response to a variety of cellular emergencies, including heat, inflammation, transformation and, at least in mice, the first embryonic cleavage. Stress can induce the movement of constitutively produced hsps to different cellular compartments; this is usually within the cell but the extracellular appearance of an hsp (Hightower and Guidon, 1989) is not entirely unprecedented. All of these observations are particularly pertinent to the circumstances in which EPF appears and help explain the rapidity of response to such a wide variety of biological events. In addition, the highly conserved nature of these molecules is consistent with our observation that the effects of EPF are neither species nor strain restricted (Morton et al., 1987) .
Identification of EPF as cpn10: implications for function
Characterizing EPF as an extracellular form of cpn10 raises two sets of questions. (1) Does regulation of the different activities and localization of EPF and cpn10 occur at the DNA, RNA or protein level and how is this controlled? (2) By what mechanism of action does EPF function in the extracellular compartment? These are difficult questions to answer and there are few precedents to follow. Much is known of the structure and regulation of the genes encoding prokaryotic cpn10 (and cpn60) (for example, the E. coli groE operon; Zeilstra-Ryalls et al., 1991) but little of the genes encoding eukaryote cpn10. Our studies to date demonstrate considerable complexity and it will be some time before question (1) can be fully addressed. Like other hsps, EPF/cpn10 appears to be a member of a large gene family, distributed across many chromosomes (K. M. Summers, G. C. Webb, G. B. Peters, R. M. Murphy, A. I. Cassady, H. Morton and A. C. Cavanagh, unpublished) ; several transcripts have been detected, indicating that more than one of these genes is likely to be functional (R. M. Murphy, R. Layfield, A. I. Cassady, D. A. Hume, A. C. Cavanagh and K. M. Summers, unpublished) . In addition, the cDNA transcribed from mRNA encoding cpn10 from both rat liver (Ryan et al., 1994) and human melanoma cells (R. M. Murphy, A. I. Cassady, K. M. Summers, M. J. Somodevilla-Torres, N. C. Hillyard, H. Morton and A. C. Cavanagh, unpublished) does not code for a classic secretory signal sequence; EPF joins a growing list of proteins that are secreted from the cytoplasm by unknown mechanisms rather than by the usual route through the endoplasmic reticulum (Muesch et al., 1990) .
As the situation is so unprecedented, it is necessary to take a very broad view of possible extracellular mechanisms of action. We envisage three alternatives.
(1) EPF/cpn10 acts as an accessory molecule to cpn60. This suggests a direct transposition of cpn60-cpn10 function to the extracellular compartment (perhaps to improve the efficiency of internalization of selected surface molecules). Reports of the appearance of cpn60 in the plasma membrane are consistent with this possibility. However, we have performed very preliminary experiments that, while not conclusive, do not support the proposition that cpn60 is the EPF 'receptor'. Anti-cpn60 antibodies have no direct effect in the EPF bioassay (anti-receptor antibodies sometimes have the same effect as the ligand), nor can they block the action of EPF.
(2) EPF/cpn10 acts as an accessory molecule to a substance(s) other than cpn60. Cpn10 stabilizes cpn60, ensuring that it can perform certain functions: in the extracellular environment, EPF/cpn10 may functionally modify a growth factor/cytokine, or a receptor for such substances, or an adhesion molecule. In short, EPF/cpn10 may regulate regulators. Strong support for this possibility comes from a recent study that demonstrates a physical interaction between cpn10 and neutrophil gelatinase associated lipocalin (Dickson et al., 1994) .
(3) EPF/cpn10 functions alone. This proposal is consistent with the body of knowledge of cell regulation by growth factors, which predicts action through a specific high-affinity cell surface receptor, with subsequent signal transduction.
Understanding the mechanism of interaction in the extracellular compartment will enable us to design specific agonists and antagonists with which the biological effects of EPF can be either enhanced or diminished. Coupled with knowledge of regulatory mechanisms, it may be possible, ultimately, to manipulate particular functions of the molecule, such as its effects on tumour growth, without causing deleterious effects on other functions, such as its constitutive role in protein folding.
